Utah Medical Products, Inc. — Q1 2022 Form 10-Q
Business context and reporting period. UTMD manufactures and markets specialty medical devices. This unaudited quarterly report covers the three months ended March 31, 2022; financial amounts below are in USD thousands unless noted.
Financial performance and position
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Net sales | $12,323 | $10,964 | +12.4% |
| Gross profit / margin | $7,533 / 61.1% | $6,947 / 63.4% | Profit +8.4% |
| Operating income / margin | $4,522 / 36.7% | $3,888 / 35.5% | +16.3% per MD&A |
| Income before tax | $4,530 | $3,898 | +16.2% |
| Net income / margin | $3,534 / 28.7% | $3,024 / 27.6% | +16.9% |
| Diluted EPS | $0.96 | $0.83 | +16.6% |
| Operating cash flow | $5,046 | $5,533 | Down $487 |
Domestic sales rose 17.7%; outside-U.S. sales rose 3.8% as reported and 7.4% in constant currency. A stronger U.S. dollar reduced reported sales by approximately $152. OEM sales were a notable domestic growth driver, while Filshie device sales declined $174 year over year. Blood Pressure Monitoring and Accessories revenue grew to $4,299 from $3,232; Gynecology/Electrosurgery/Urology was $5,102 versus $5,127.
Gross margin contracted 2.3 percentage points, principally due to higher raw-material and freight costs (each reported as up more than 20%), higher U.S. labor and manufacturing overhead, and elevated self-insured employee medical costs. Approximately 6% broad-based device and component price increases helped offset cost pressure. Higher sales and largely fixed operating expenses supported operating-margin expansion. The effective tax provision rate declined to 22.0% from 22.4%.
Adjusted EBITDA, a non-GAAP measure defined by the company, was $6,371 (51.7% of sales), compared with $5,776 (52.7%).
Cash and investments were $65,873 at March 31, 2022, versus $60,974 at year-end. The company reported no debt. Total assets were $119,803 and stockholders’ equity $109,168. Current assets were $79,480 and current liabilities $6,098; the current ratio was 13.0, down from 19.5 at year-end. Working capital increased $3,970 to $73,383. Receivables rose $589 and average collection age increased to 42 days from 36; inventories rose $771, partly as a hedge against supply-chain disruption. Capital expenditures were $237, primarily for manufacturing capacity, and management expects further investment for the same OEM customer.
Changes, outlook and risks
- Cash generation and capital allocation: Cash from operations decreased year over year, with increased inventory and receivables among the factors. Cash dividends paid in Q1 were zero; the special $7,309 dividend declared in Q4 2021 was paid in December 2021. The equity statement separately records $1,060 of common-stock dividends in Q1 2022, a timing/reconciliation item to verify.
- Intangible amortization: Amortization of the CSI Filshie U.S. distribution-rights asset was $1,105 for the quarter; the asset is expected to be fully amortized in Q3 2023. Total net intangible assets declined to $15,423.
- Management outlook: Based on Q1 results, management expected to achieve its 2022 plan, without providing numerical guidance in this filing. Priorities include integrating multinational operations, marketing the Filshie system in the U.S., developing products, investing in capacity and technology, pursuing accretive acquisitions, and returning excess capital through dividends or repurchases when appropriate.
- Key risks and contingencies: Management cited inflationary input costs, supply-chain and COVID-related disruption, foreign-exchange movements, medical-device regulation and approval delays, healthcare purchasing constraints, product liability, reliance on distributors, and retention of key employees. The company manages currency exposure without separate hedging transactions. It said existing litigation was not expected to materially affect financial results; no warranty reserve was recorded because estimated obligations were considered immaterial.
- Controls and subsequent events: Management concluded disclosure controls were effective as of March 31, 2022, and reported no material change in internal control over financial reporting. No material subsequent events requiring disclosure were identified.
Investor verification points
- Confirm the Q1 dividend accounting and timing: $1,060 recorded in the statement of equity versus no Q1 cash dividend paid in the cash-flow statement and management discussion.
- Assess whether cost inflation, pricing actions, and planned capacity spending will preserve gross margins and convert sales growth into cash.
- Track receivables aging, inventory levels, and supply availability, given slower collections and inventory buildup.
- Monitor currency effects: foreign-currency sales were 24% of consolidated sales and reported Q1 sales were reduced by a stronger dollar.
- Compare full-year results with management’s expectation of achieving its 2022 plan; the filing provides no numerical forecast.